Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Encision Inc. (ECIA) reported its fiscal 2025 third quarter results ending December 31, 2024. The company posted total net revenue of $1.59 million, comprising $1.46 million in product revenue and $128,000 in service revenue, with a quarterly net loss of $24,000 or $(0.00) per diluted share.
For the nine-month period, total net revenue was $4.97 million with a net loss of $172,900 or $(0.01) per diluted share. Gross margin on product revenue improved to 54% in Q3 FY2025 from 46% in Q3 FY2024. The company is developing a new product for ENT surgery, expected to launch in the first half of FY2026.
The quarter was described as a rebuilding period, with new sales partners onboarded and internal cost reduction measures implemented, expected to show effects from Q4 onwards.
Encision Inc. (ECIA) ha riportato i risultati del terzo trimestre dell’anno fiscale 2025, conclusosi il 31 dicembre 2024. L’azienda ha registrato un fatturato netto totale di 1,59 milioni di dollari, di cui 1,46 milioni di dollari provenienti da vendite di prodotti e 128.000 dollari da servizi, con una perdita netta trimestrale di 24.000 dollari, ovvero $(0,00) per azione diluita.
Per il periodo di nove mesi, il fatturato netto totale è stato di 4,97 milioni di dollari con una perdita netta di 172.900 dollari, ovvero $(0,01) per azione diluita. Il margine lordo sulle vendite di prodotti è migliorato al 54% nel terzo trimestre dell’anno fiscale 2025, rispetto al 46% nel terzo trimestre dell’anno fiscale 2024. L’azienda sta sviluppando un nuovo prodotto per la chirurgia ENT, previsto per il lancio nella prima metà dell’anno fiscale 2026.
Il trimestre è stato descritto come un periodo di ricostruzione, con nuovi partner di vendita integrati e misure interne di riduzione dei costi attuate, i cui effetti sono attesi a partire dal quarto trimestre.
Encision Inc. (ECIA) reportó sus resultados del tercer trimestre del año fiscal 2025, que finalizó el 31 de diciembre de 2024. La compañía registró unos ingresos netos totales de 1,59 millones de dólares, que incluyen 1,46 millones de dólares en ingresos por productos y 128.000 dólares en ingresos por servicios, con una pérdida neta trimestral de 24.000 dólares o $(0,00) por acción diluida.
Durante el período de nueve meses, los ingresos netos totales fueron de 4,97 millones de dólares con una pérdida neta de 172.900 dólares o $(0,01) por acción diluida. El margen bruto sobre los ingresos por productos mejoró al 54% en el tercer trimestre del año fiscal 2025, en comparación con el 46% en el tercer trimestre del año fiscal 2024. La compañía está desarrollando un nuevo producto para cirugía ENT, que se espera lanzar en la primera mitad del año fiscal 2026.
El trimestre fue descrito como un período de reconstrucción, con nuevos socios de ventas incorporados y medidas internas de reducción de costos implementadas, cuyos efectos se esperan a partir del cuarto trimestre.
Encision Inc. (ECIA)는 2024년 12월 31일로 종료되는 2025 회계연도 제3분기 실적을 발표했습니다. 회사는 총 순수익 159만 달러를 기록했으며, 여기에는 제품 매출 146만 달러와 서비스 매출 12만8천 달러가 포함됩니다. 분기 순손실은 2만4천 달러로, 희석 주당 $(0.00)입니다.
9개월 동안의 총 순수익은 497만 달러였으며, 순손실은 17만2천9백 달러로, 희석 주당 $(0.01)입니다. 제품 매출의 총 마진은 2025 회계연도 3분기에 54%로 개선되었으며, 2024 회계연도 3분기의 46%에서 증가했습니다. 회사는 2026 회계연도 상반기에 출시될 예정인 ENT 수술용 신제품을 개발하고 있습니다.
이번 분기는 새로운 판매 파트너가 온보딩되고 내부 비용 절감 조치가 시행된 재건 기간으로 설명되었습니다. 이 조치는 4분기부터 효과를 나타낼 것으로 예상됩니다.
Encision Inc. (ECIA) a annoncé ses résultats du troisième trimestre de l’exercice 2025, se terminant le 31 décembre 2024. L’entreprise a affiché un chiffre d’affaires net total de 1,59 million de dollars, comprenant 1,46 million de dollars de revenus produit et 128 000 dollars de revenus de services, avec une perte nette trimestrielle de 24 000 dollars ou $(0,00) par action diluée.
Pour la période de neuf mois, le chiffre d’affaires net total s’élevait à 4,97 millions de dollars avec une perte nette de 172 900 dollars ou $(0,01) par action diluée. La marge brute sur les revenus produits a augmenté à 54 % au T3 de l’exercice 2025, contre 46 % au T3 de l’exercice 2024. L’entreprise développe un nouveau produit pour la chirurgie ORL, qui devrait être lancé dans la première moitié de l’exercice 2026.
Le trimestre a été décrit comme une période de reconstruction, avec de nouveaux partenaires de vente intégrés et des mesures internes de réduction des coûts mises en œuvre, dont les effets devraient se faire sentir à partir du quatrième trimestre.
Encision Inc. (ECIA) hat die Ergebnisse des dritten Quartals des Geschäftsjahres 2025 bekannt gegeben, das am 31. Dezember 2024 endete. Das Unternehmen erzielte einen Gesamtumsatz von 1,59 Millionen Dollar, bestehend aus 1,46 Millionen Dollar aus Produktverkäufen und 128.000 Dollar aus Dienstleistungen, mit einem quartalsweisen Nettoverlust von 24.000 Dollar oder $(0,00) pro verwässerter Aktie.
Für den Neunmonatszeitraum betrug der Gesamtumsatz 4,97 Millionen Dollar mit einem Nettoverlust von 172.900 Dollar oder $(0,01) pro verwässerter Aktie. Die Bruttomarge bei den Produktverkäufen verbesserte sich im dritten Quartal des Geschäftsjahres 2025 auf 54% gegenüber 46% im dritten Quartal des Geschäftsjahres 2024. Das Unternehmen entwickelt ein neues Produkt für die HNO-Chirurgie, das in der ersten Hälfte des Geschäftsjahres 2026 auf den Markt kommen soll.
Das Quartal wurde als Wiederaufbauphase beschrieben, in der neue Vertriebspartner gewonnen und interne Kostensenkungsmaßnahmen umgesetzt wurden, von denen erwartet wird, dass sie ab dem vierten Quartal Wirkung zeigen.
Positive
- Gross margin improvement from 46% to 54% year-over-year in Q3
- Reduced quarterly net loss from $207,000 to $24,000 year-over-year
- Cost reduction measures implemented with effects expected from Q4
- Cash position increased to $347,919 from $42,509 at fiscal year start
Negative
- Product revenue declined from $1.56M to $1.46M in Q3 year-over-year
- Nine-month total revenue decreased from $5.1M to $4.97M year-over-year
- Line of credit increased from $156,685 to $281,527
- Operating loss of $20,867 in Q3 FY2025
BOULDER, CO / ACCESS Newswire / February 14, 2025 / Encision Inc. (OTC PINK:ECIA), a medical device company that owns the patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2025 third quarter that ended December 31, 2024.
The Company posted quarterly product net revenue of $1.46 million and service net revenue of $128 thousand, or total net revenue of $1.59 million for a quarterly net loss of $24 thousand, or $(0.00) per diluted share. These results compare to product net revenue of $1.56 million and service net revenue of $20 thousand, or total net revenue of $1.58 million for a quarterly net loss of $207 thousand, or $(0.02) per diluted share, in the year-ago quarter. Gross margin on product net revenue was 54% in the fiscal 2025 third quarter and 46% in the fiscal 2024 third quarter.
The Company posted nine months of product net revenue of $4.7 million and service net revenue of $268 thousand, or total net revenue of $4.97 million for a nine-month net loss of $172.9 thousand, or $(0.01) per diluted share. These results compare to product net revenue of $4.93 million and service net revenue of $134.3 thousand, or total net revenue of $5.1 million for a nine-month net loss of $355 thousand, or $(0.03) per diluted share, in the year-ago nine months. Gross margin on product net revenue was 52.7% in the fiscal 2025 nine months and 48.5.7% in the fiscal 2024 nine months.
“The third quarter was a rebuilding period for Encision,” said Gregory Trudel, President & CEO of Encision. “While we were able to bring additional sales partners online, the timing was insufficient for them to make substantial contributions to the top line. During this period, we implemented enhancements to reduce internal costs. The effects of those efforts will be evident beginning in Q4. We continue to make significant progress in the development of our new product for ENT surgery and are on track to share that with the market in the first half of FY2026.”
Encision Inc. designs and markets a portfolio of high-performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company’s actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company’s distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delays in developing new products and receiving FDA approval for such new products and other factors discussed in the Company’s filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024, and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.
CONTACT: Brandon Shepard, Encision Inc., 303-444-2600, bshepard@encision.com
Encision Inc.
Condensed Balance Sheets
|
December 31, 2024 |
March 31, 2024 |
|||||||
|
Unaudited |
Audited |
|||||||
|
ASSETS |
||||||||
|
Current assets: |
||||||||
|
Cash |
$ |
347,919 |
$ |
42,509 |
||||
|
Accounts receivable |
779,900 |
891,129 |
||||||
|
Inventories |
1,363,377 |
1,402,338 |
||||||
|
Prepaid expenses |
195,455 |
90,298 |
||||||
|
Total current assets |
2,686,651 |
2,426,274 |
||||||
|
Equipment: |
||||||||
|
Furniture, fixtures, and equipment, at cost |
2,675,406 |
2,627,726 |
||||||
|
Accumulated depreciation |
(2,405,638 |
) |
(2,373,722 |
) |
||||
|
Equipment, net |
269,768 |
254,004 |
||||||
|
Right of use asset, net |
653,249 |
900,787 |
||||||
|
Patents, net |
175,233 |
164,010 |
||||||
|
Other assets |
73,826 |
65,641 |
||||||
|
TOTAL ASSETS |
3,858,727 |
3,810,716 |
||||||
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
||||||||
|
Current liabilities: |
||||||||
|
Accounts payable |
$ |
495,015 |
$ |
346,049 |
||||
|
Line of credit |
281,527 |
156,685 |
||||||
|
Secured notes |
47,469 |
42,194 |
||||||
|
Accrued compensation |
225,252 |
184,913 |
||||||
|
Other accrued liabilities |
140,593 |
119,804 |
||||||
|
Accrued lease liability |
421,467 |
370,377 |
||||||
|
Total current liabilities |
1,611,323 |
1,220,022 |
||||||
|
Long-term liability: |
||||||||
|
Secured notes |
182,067 |
67,336 |
||||||
|
Accrued lease liability |
377,952 |
696,610 |
||||||
|
Total liabilities |
2,171,342 |
1,983,968 |
||||||
|
Commitments and contingencies (Note 4) |
||||||||
|
Shareholders’ equity: |
||||||||
|
Preferred stock, no par value: 10,000,000 shares authorized; none issued and outstanding |
— |
— |
||||||
|
Common stock and additional paid-in capital, no par value: 100,000,000 shares authorized; 11,879,645 and 11,858,627 issued and outstanding at December 31, 2024, and March 31, 2024, respectively |
24,405,321 |
24,371,795 |
||||||
|
Accumulated (deficit) |
(22,717,936 |
) |
(22,545,047 |
) |
||||
|
Total shareholders’ equity |
1,687,385 |
1,826,748 |
||||||
|
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY |
$ |
3,858,727 |
$ |
3,810,716 |
||||
Encision Inc.
Condensed Statements of Operations
(Unaudited)
|
Three Months Ended |
Nine Months Ended |
|||||||||||||||
|
December 31, 2024 |
December 31, 2023 |
December 31, 2024 |
December 31, 2023 |
|||||||||||||
|
NET REVENUE: |
||||||||||||||||
|
Product |
$ |
1,457,402 |
$ |
1,561,103 |
$ |
4,703,181 |
$ |
4,927,069 |
||||||||
|
Service |
128,179 |
20,461 |
268,718 |
134,269 |
||||||||||||
|
Total revenue |
1,585,581 |
1,581,564 |
4,971,899 |
5,061,338 |
||||||||||||
|
COST OF REVENUE: |
||||||||||||||||
|
Product |
667,004 |
843,216 |
2,217,524 |
2,539,708 |
||||||||||||
|
Service |
68,287 |
11,109 |
132,941 |
69,057 |
||||||||||||
|
Total cost of revenue |
735,291 |
854,325 |
2,350,465 |
2,608,765 |
||||||||||||
|
GROSS PROFIT |
850,290 |
727,239 |
2,621,434 |
2,452,573 |
||||||||||||
|
OPERATING EXPENSES: |
||||||||||||||||
|
Sales and marketing |
377,153 |
413,992 |
1,258,870 |
1,236,770 |
||||||||||||
|
General and administrative |
355,200 |
351,569 |
1,080,507 |
1,106,703 |
||||||||||||
|
Research and development |
138,804 |
151,077 |
433,500 |
420,351 |
||||||||||||
|
Total operating expenses |
871,157 |
916,638 |
2,772,877 |
2,763,824 |
||||||||||||
|
OPERATING INCOME (LOSS) |
(20,867 |
) |
(189,399 |
) |
(151,443 |
) |
(311,251 |
) |
||||||||
|
Interest expense, net |
(9,508 |
) |
(21,065 |
) |
(26,475 |
) |
(52,148 |
) |
||||||||
|
Other income (expense), net |
5,707 |
3,334 |
5,028 |
8,287 |
||||||||||||
|
Interest expense and other income |
(3,801 |
) |
(17,731 |
) |
(21,447 |
) |
(43,861 |
) |
||||||||
|
(LOSS) BEFORE PROVISION FOR INCOME TAXES |
(24,668 |
) |
(207,130 |
) |
(172,890 |
) |
(355,112 |
) |
||||||||
|
Provision for income taxes |
— |
— |
— |
— |
||||||||||||
|
NET (LOSS) |
$ |
(24,668 |
) |
$ |
(207,130 |
) |
$ |
(172,890 |
) |
$ |
(355,112 |
) |
||||
|
Net (loss) per share-basic and diluted |
$ |
(0.00 |
) |
$ |
(0.02 |
) |
$ |
(0.01 |
) |
$ |
(0.03 |
) |
||||
|
Weighted average shares-basic and diluted |
11,877,469 |
11,769,543 |
11,875,917 |
11,769,543 |
||||||||||||
Encision Inc.
Condensed Statements of Cash Flows
(Unaudited)
|
Nine Months Ended |
December 31, 2024 |
December 31, 2023 |
||||||
|
Cash flows (used in) operating activities: |
||||||||
|
Net (loss) |
(172,890 |
) |
(355,112 |
) |
||||
|
Adjustments to reconcile net (loss) to net cash (used in) operating activities: |
||||||||
|
Depreciation and amortization |
57,855 |
64,357 |
||||||
|
Stock-based compensation expense related to stock options |
34,975 |
53,306 |
||||||
|
Provision for inventory obsolescence, net change |
7,281 |
63,000 |
||||||
|
Change in operating assets and liabilities: |
||||||||
|
Right of use asset, net |
(20,030 |
) |
(29,664 |
) |
||||
|
Accounts receivable |
111,230 |
(2,391 |
) |
|||||
|
Inventories |
31,680 |
282,017 |
||||||
|
Prepaid expenses and other assets |
(113,343 |
) |
(30,055 |
) |
||||
|
Accounts payable |
148,967 |
48,876 |
||||||
|
Accrued compensation and other accrued liabilities |
61,129 |
61,018 |
||||||
|
Net cash provided by (used in) operating activities |
146,854 |
155,352 |
||||||
|
Cash flows (used in) investing activities: |
||||||||
|
Acquisition of property and equipment |
(61,334 |
) |
(12,051 |
) |
||||
|
Patent costs |
(23,509 |
) |
(20,177 |
) |
||||
|
Net cash (used in) investing activities |
(84,843 |
) |
(32,228 |
) |
||||
|
Cash flows from financing activities: |
||||||||
|
Borrowing from line of credit |
281,527 |
— |
||||||
|
(Payments) from options exercised |
(1,449 |
) |
— |
|||||
|
(Paydown) Secured notes |
(36,679 |
) |
(212,851 |
) |
||||
|
Net cash provided by (used in) financing activities |
243,399 |
(212,851 |
) |
|||||
|
Net increase in cash |
305,410 |
(89,727 |
) |
|||||
|
Cash, beginning of fiscal year |
42,509 |
188,966 |
||||||
|
Cash, end of fiscal quarter |
347,919 |
99,239 |
||||||
|
Supplemental disclosures of cash flow information: |
||||||||
|
Cash paid during the year for interest |
$ |
26,475 |
$ |
52,148 |
||||
SOURCE: Encision, Inc.
View the original press release on ACCESS Newswire
FAQ
What was Encision’s (ECIA) revenue for Q3 FY2025?
Encision reported total net revenue of $1.59 million for Q3 FY2025, consisting of $1.46 million in product revenue and $128,000 in service revenue.
How did ECIA’s gross margin change in Q3 FY2025 compared to Q3 FY2024?
Gross margin on product revenue improved to 54% in Q3 FY2025 from 46% in Q3 FY2024.
What is the timeline for ECIA’s new ENT surgery product launch?
Encision plans to launch its new ENT surgery product in the first half of FY2026.
How much did ECIA’s net loss improve in Q3 FY2025?
ECIA’s net loss improved to $24,000 in Q3 FY2025 from $207,000 in Q3 FY2024.
What was ECIA’s cash position as of December 31, 2024?
Encision’s cash position was $347,919 as of December 31, 2024, up from $42,509 at the start of the fiscal year.
